{"id":"W4400014677","doi":"10.1111/cea.14527","title":"The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation","year":2024,"lang":"en","type":"article","venue":"Clinical & Experimental Allergy","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; McGill University; University of Toronto; Montreal Children's Hospital","funders":"KalVista Pharmaceuticals; Genentech; LEO Pharma; Eli Lilly and Company; Ono Pharmaceutical; Celltrion; Eisai; Intellia Therapeutics; Grifols; GlaxoSmithKline; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ipsen; Glenmark Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; BioCryst; Ionis Pharmaceuticals; Celldex Therapeutics; AstraZeneca; CSL Behring; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; Takeda Pharmaceutical Company; Amgen; Pfizer","keywords":"Medicine; Angioedema; Health care; Specialty; Disease registry; Observational study; Disease; Family medicine; Pathology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.193495,0.001495829,0.00189562,0.0086735,0.002682585,0.007303082,0.005890251,0.003420335,0.02152827],"category_scores_gemma":[0.1678118,0.001931677,0.002124837,0.009080763,0.004050649,0.005029366,0.009696953,0.00646303,0.009923747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005646496,"about_ca_system_score_gemma":0.04314116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00555785,"about_ca_topic_score_gemma":0.005990108,"domain_scores_codex":[0.8737921,0.08296262,0.0180425,0.006109162,0.01658373,0.002509807],"domain_scores_gemma":[0.8475284,0.05494031,0.01556863,0.0194508,0.04709361,0.01541825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0079771,0.006128671,0.09181058,0.02033628,0.0006965846,0.0007889489,0.009052243,0.002580844,0.001276479,0.06758799,0.2818772,0.509887],"study_design_scores_gemma":[0.006779704,0.005044457,0.1093274,0.03712661,0.001037569,0.00115484,0.006902123,0.004572895,0.00239856,0.01890323,0.8061674,0.0005852479],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01496663,0.006533116,0.07954084,0.01426498,0.002267568,0.8236084,0.04160866,0.000914906,0.01629486],"genre_scores_gemma":[0.02342446,0.003899412,0.1966189,0.00570338,0.001398346,0.7399489,0.02611013,0.0004072552,0.002489214],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.193495,"threshold_uncertainty_score":0.9945643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04211469504800174,"score_gpt":0.4773435709421989,"score_spread":0.4352288758941971,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}